CN Patent

CN110621316B — 用ehmt2抑制剂进行的组合疗法

Assigned to Epizyme Inc · Expires 2024-01-26 · 2y expired

What this patent protects

本披露涉及通过将EHMT2抑制剂或包含EHMT2抑制剂化合物和本文披露的一种或多种另外的治疗剂的组合或其药物组合物施用于有需要的受试者来预防或治疗癌症的方法。本披露还涉及此类化合物或组合用于研究或其他非治疗目的的用途。

USPTO Abstract

本披露涉及通过将EHMT2抑制剂或包含EHMT2抑制剂化合物和本文披露的一种或多种另外的治疗剂的组合或其药物组合物施用于有需要的受试者来预防或治疗癌症的方法。本披露还涉及此类化合物或组合用于研究或其他非治疗目的的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN110621316B
Jurisdiction
CN
Classification
—
Expires
2024-01-26
Drug substance claim
No
Drug product claim
No
Assignee
Epizyme Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.